T1	Participants 48 165	patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events
T2	Participants 672 748	5238 patients with type 2 diabetes who had evidence of macrovascular disease
T3	Participants 2410 2485	patients with type 2 diabetes who have a high risk of macrovascular events.
